Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

May 31, 2004

Study Completion Date

April 30, 2008

Conditions
Liver Cancer
Interventions
DRUG

docetaxel

DRUG

gemcitabine hydrochloride

Trial Locations (17)

32224

Mayo Clinic, Jacksonville

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

96813

MBCCOP - Hawaii, Honolulu

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

30342-1701

CCOP - Atlanta Regional, Atlanta

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

58501-5505

Medcenter One Health System, Bismarck

43623-3456

CCOP - Toledo Community Hospital, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00006010 - Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter